The first half of 2026 was highly uneven across biopharma and life sciences stocks, including pharma, biotech, diagnostics, life sciences tools, CDMOs, and specialty therapeutics.
Several companies delivered strong gains, led by Moderna, WuXi AppTec, Bayer, Exelixis, Johnson & Johnson, West Pharmaceutical Services, Zydus Group, Torrent Pharmaceuticals Ltd, Quest Diagnostics, and Merck.
Others faced meaningful declines, including Zoetis, Insmed Incorporated, Bausch Health Companies Inc., CSL, Grifols, Daiichi Sankyo US, and Alnylam Pharmaceuticals.
Short-term stock performance is never a complete measure of long-term value creation. But the first half of 2026 suggests a recalibration of investor expectations across parts of the biopharma sector.
For some investors, this reset may create opportunities where the underlying fundamentals remain strong.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.